Scholar Rock Holding Corporation $SRRK Shares Bought by Voya Investment Management LLC

Voya Investment Management LLC lifted its stake in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 18.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 443,155 shares of the company’s stock after purchasing an additional 67,839 shares during the quarter. Voya Investment Management LLC owned about 0.46% of Scholar Rock worth $16,503,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Northern Trust Corp boosted its holdings in Scholar Rock by 2.5% during the first quarter. Northern Trust Corp now owns 765,280 shares of the company’s stock worth $24,604,000 after buying an additional 18,753 shares in the last quarter. Hsbc Holdings PLC grew its holdings in shares of Scholar Rock by 27.4% in the 1st quarter. Hsbc Holdings PLC now owns 16,883 shares of the company’s stock worth $529,000 after acquiring an additional 3,627 shares during the period. AlphaQuest LLC grew its holdings in shares of Scholar Rock by 490.7% in the 1st quarter. AlphaQuest LLC now owns 5,417 shares of the company’s stock worth $174,000 after acquiring an additional 4,500 shares during the period. Corebridge Financial Inc. increased its stake in Scholar Rock by 2.2% in the 1st quarter. Corebridge Financial Inc. now owns 39,389 shares of the company’s stock valued at $1,266,000 after purchasing an additional 850 shares in the last quarter. Finally, Rafferty Asset Management LLC boosted its position in shares of Scholar Rock by 43.0% in the 1st quarter. Rafferty Asset Management LLC now owns 111,671 shares of the company’s stock worth $3,590,000 after buying an additional 33,594 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Stock Up 3.0%

Shares of NASDAQ:SRRK opened at $45.20 on Tuesday. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. The firm has a market cap of $4.61 billion, a price-to-earnings ratio of -14.35 and a beta of 0.60. The stock’s 50-day moving average price is $36.66 and its two-hundred day moving average price is $35.63. Scholar Rock Holding Corporation has a 12-month low of $22.71 and a 12-month high of $48.28.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same period last year, the firm posted ($0.66) EPS. On average, research analysts forecast that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Insider Transactions at Scholar Rock

In related news, insider Mo Qatanani sold 136,462 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $45.21, for a total value of $6,169,447.02. Following the transaction, the insider directly owned 108,964 shares of the company’s stock, valued at approximately $4,926,262.44. This trade represents a 55.60% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Srinivas Akkaraju purchased 29,599 shares of the company’s stock in a transaction on Tuesday, October 7th. The shares were purchased at an average price of $39.92 per share, with a total value of $1,181,592.08. Following the completion of the purchase, the director directly owned 530,038 shares of the company’s stock, valued at $21,159,116.96. The trade was a 5.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 530,038 shares of company stock worth $19,988,928 in the last ninety days. Insiders own 13.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on SRRK shares. HC Wainwright cut their price objective on Scholar Rock from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, September 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Wednesday, October 8th. Leerink Partnrs upgraded Scholar Rock to a “strong-buy” rating in a research report on Monday, September 15th. BMO Capital Markets reiterated an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Friday, November 14th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Four investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Scholar Rock currently has an average rating of “Buy” and a consensus target price of $48.92.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).